Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00359892 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Hodgkin's Lymphoma
A Phase 2 study, sponsored by Gemin X.
- Completed
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT00359892 is a Phase 2 study that has completed, run by Gemin X. The registered enrollment target is 13 participants.
The verdict
NCT00359892, a Phase 2 study, has completed, sponsored by Gemin X.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
Defects in the apoptotic process can lead to the onset of cancer by allowing cells to grow unchecked when an oncogenic signal is present. Obatoclax is designed to restore apoptosis through inhibition of the Bcl-2 family of proteins, thereby reinstating the natural process of cell death that is often inhibited in cancer cells. This is a multi-center, open-label, Phase II study of single-agent obatoclax administered in 2-week cycles as a 24-hour infusion every 2 weeks at a fixed dose of 60 mg to patients with relapsed or refractory Hodgkin's Lymphoma. Infusions may be administered on an out-patient basis. No investigational or commercial agents or therapies other than those described in the protocol may be administered with the intent to treat the patient's malignancy. Supportive care measures including those directed at controlling symptoms resulting from Hodgkin's Lymphoma (blood products, growth factor, etc.) are allowed.
Interventions
- DRUG Obatoclax mesylate (GX15-070MS)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2006-07 |
| Est. Completion | 2008-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00359892
The ClinicalTrials.gov registry entry for NCT00359892 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gemin X, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Obatoclax mesylate (GX15-070MS) is the first listed.
NCT00359892 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00359892 about?
NCT00359892 is a clinical study titled "Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Hodgkin's Lymphoma". Defects in the apoptotic process can lead to the onset of cancer by allowing cells to grow unchecked when an oncogenic signal is present. Obatoclax is designed to restore apoptosis through inhibition of the Bcl-2 family of proteins, thereby reinstating the natural process of cell death that is often...
What is the current status of trial NCT00359892?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2006-07. Estimated completion is 2008-11.
What interventions are being tested in trial NCT00359892?
The interventions under investigation include: Obatoclax mesylate (GX15-070MS) (DRUG).
Who is sponsoring clinical trial NCT00359892?
This trial is sponsored by Gemin X, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.